Overview
Status
Active
Registry date
2013-03-22
Share capital
15,000.00 PLN
Registered address
ul. Komandosów 1/4, 32-085 Modlniczka, Poland
Electronic delivery address
AE:PL-23754-95577-IAAJI-28
Financials
Revenue history (in k)
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 280 days for 2024).
- 2025filed
- 202421/04/2026
- 202317/03/2025
- 202231/03/2023
- 202130/09/2022
- 202026/08/2021
Filed on timeDelayFiling deadline
The statements for 2025 report only zeros (no activity).
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Division · Manufacture of basic pharmaceutical products and pharmaceutical preparations315 / 330
Top 95%
Voivodeship · Małopolskie43,778 / 46,035
Top 95%
Country · Poland471,516 / 495,867
Top 95%
Results vs industry
Revenue
This companyUSD 47.94MedianUSD 919.05kAverageUSD 25.83m
Net profit
This companyUSD -11.31kMedianUSD 14.92kAverageUSD 2.77m
Operating costs
This companyUSD 3.36kMedianUSD 873.06kAverageUSD 21.43m
Assets
This companyUSD 8.43kMedianUSD 897.46kAverageUSD 31.52m
Industry
Authorized Representatives
Jarosław Rafał Ogórekage 55 – President of the Management Board
Manner of representation
If the management board is a multi-member management board, two members of the management board or a member of the management board jointly with a commercial proxy are authorised to make declarations of will and sign on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Robert Birontage 58 | 50 | $1,350.62 | 33.3333% |
Jarosław Rafał Ogórekage 55 | 50 | $1,350.62 | 33.3333% |
Leszek Pamułaage 63 | 50 | $1,350.62 | 33.3333% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2018-05-01.
36 2490 1057 0000 9902 1447 7430
45 2490 1057 0000 9900 1447 7430
Debt
1 closed proceeding recorded in KRZ history.
| Registration date | Proceeding type | Status | |
|---|---|---|---|
| Nov 29, 2023 | Petition to declare entrepreneur bankruptcy | Closed |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 14, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $18,462$18,462 | Polski Fundusz Rozwoju S.A. |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Instytut Biotechnologii Surowic i Szczepionek Biomed - Skrót Firmy Ibss BiomedS.A. | $37,103,878.54 | biomed.pl | ||
| Fagronsp. z o.o. | $21,715,187.73 | fagron.pl | ||
| Krakowskie Zakłady Zielarskie Herbapol w KrakowieS.A. | $7,294,338.51 | herbapol.krakow.pl | ||
| F1 PharmaS.A. | $272,113.66 | f1pharma.pl | ||
| Ampliconsp. z o.o. | $48,330.99 | amplicon.pl | ||
| Xenira Pharmaceuticalssp. z o.o. | $26,670.82 | xenirapharma.com | ||
| Sanford Biotechsp. z o.o. | $2,586.64 | sanfordbiotech.com | ||
| Cefeasp. z o.o. | $294.66 | cefea.pl | ||
| Auxilius PharmaS.A. | $0.83 | auxiliuspharma.com | ||
| Zakład Farmaceutyczny Amarasp. j. | $0.00 | amara.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-06-19 | Name change (Retinea Pharma → Inspire Pharma) | |
| 2019-10-23 | Address change (Ul. Żywiczna 19a, 05-092, Łomianki → Ul. Komandosów 1/4, 32-085, Modlniczka) | |
| 2019-10-23 | Share capital increase (5,000.00 PLN → 15,000.00 PLN) | |
| 2018-03-13 | Address change (Towarowa 1, 10-416, Olsztyn → Ul. Żywiczna 19a, 05-092, Łomianki) | |
| 2018-03-13 | Name change (Vita → Retinea Pharma) |
FAQ
The main business activity of Inspire Pharma focuses on manufacture of pharmaceutical preparations.
The company was registered in the Polish National Court Register (KRS) on March 22, 2013.
The headquarters is located at: ul. Komandosów 1, 32-085 Modlniczka.
The share capital of the company is PLN 15,000 (approx. $4,052).
The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.
The company reported a revenue of $48 in 2024, which is a decrease of 99.6% compared to 2023.
No, in 2024 the company was not profitable, reporting a net loss of $11,314. For comparison, in 2023 the loss was $24,870, meaning the company reduced its loss by 56.8%.
The largest operating cost category falls under external services. This category amounted to $3,357 in 2024, representing 100% of all operating expenses.
Last updated: 2026-04-25